Ask this question - if Australian decision-makers can disregard the human impact of delays in reimbursed access to health technologies, why should they be excused from considering the broader consequences?
Challenging headlines are the natural consequence of disrupting a very stale debate
April 15, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News -
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - - Latest News -
Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances
November 26, 2025 - - Australian Biotech -
Slade Pharmacy marks anniversary with record research contributions at conferences
November 26, 2025 - - Latest News -
US secures significant price reductions on 15 medicines in second round of medicare negotiations
November 26, 2025 - - Latest News -
The US and UK edging closer to an agreement on pharmaceutical pricing
November 26, 2025 - - Latest News
